The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Nauzene Chewables Ginger Honey
Sodium citrate · TRISODIUM CITRATE DIHYDRATE 230 mg/1 · Tablet, Chewable · Oral · Kobayashi Healthcare International, Inc.
NDC 52389-0677-42 · 3 BLISTER PACK in 1 CARTON / 14 TABLET, CHEWABLE in 1 BLISTER PACK · OTC MONOGRAPH DRUG · View full market →
Medicare Part D
Medicare Part D does not cover over-the-counter drugs — by law it pays only for products requiring a prescription.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- M001
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Sodium citrate (Tablet, Chewable)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Kobayashi Healthcare International, Inc. | TRISODIUM CITRATE DIHYDRATE 230 mg/1 | Jul 15, 2026 | Sep 3, 2026 |
| Contract Pharmacal Corp. | TRISODIUM CITRATE DIHYDRATE 230 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Nauzene Chewables Ginger Honey — NDC 52389-0677-42," retrieved September 3, 2026, https://drugdashboards.com/drug/52389067742.
Free to cite with attribution — see how the data is put together.